09:41 AM EST - Immunotec Inc. : said the U.S. Food and Drug Administration has approved an investigator-held IND to conduct a pilot study of 48 patients to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV non-small cell lung cancer or NSCLC. IMN 1207 is an advanced formulation of the undenatured whey protein, Immunocal, a dietary natural health supplement developed and sold worldwide by Immunotec for the past 12 years. The study, which compares the use of IMN 1207 with casein, another protein that is derived from milk, proposes that the use of IMN 1207 could potentially maintain or increase weight in patients with advanced NSCLC. Immunotec Inc.
shares T.IMM are trading even at $0.45.
